Current Issues in the Management of Patients with Hodgkin’s Disease
There is currently great and often heated debate over some important aspects of the management of patients with Hodgkin’s disease. New data concerning the proper staging of patients have been developed at several centers, but these data and their implications for staging and management have not been universally accepted. Research at several institutions has indicated that a combined modality approach to some patients with early stage disease offers the best chance of prolonged disease free survival. However, some investigators have argued that overall survival is not enhanced by such aggressive treatment because “salvage” chemotherapy will cure a significant fraction of radiation failures. “Salvage” therapy, however, has not been so effective in all studies. Those who favor the radiotherapy alone approach to all patients with early stage disease argue additionally that the frequency of second malignancies in patients with Hodgkin’s disease is greatest in patients who receive intensive combined modality therapy. Others point out that, while this may be true, closer examination of relevant data demonstrates that the incidence of second malignancies is greatest in patients who receive intensive radiotherapy initially, relapse, and then receive intensive combination chemotherapy as reinduction treatment. It must be noted that such reinduction chemotherapy constitutes “salvage” therapy.
KeywordsToxicity Lymphoma Leukemia Iodine Oncol
Unable to display preview. Download preview PDF.
- 1.Rosenberg, SA, HS Kaplan, E Glatstein, and CS Portlock, The role of adjuvant MOPP in the radiation therapy of Hodgkin’s disease: A progress report after eight years on the Stanford trials. In: Adjuvant Therapy of Cancer, Salmon SS, and SE Jones (eds), -North Holland, p 505–516, 1977Google Scholar
- 2.Rosenberg, SA, HS Kaplan, E Glatstein, and CS Portlock, The role of adjuvant MOPP in the radiation therapy of Hodgkin’s disease: A progress report after eight years on the Stanford trials. In: Adjuvant Therapy of Cancer, Salmon SS, and SE Jones (eds), -North Holland, p 505–516, 1977Google Scholar
- 4.Coleman, CN, CJ Williams, A Flint, et al, Hematologic neoplasia in patients treated for Hodgkin’s disease. New Engl J Med 297: 1249 1252, 1977Google Scholar
- 12.Torti, FM, CS Portlock, SA Rosenberg, and HS Kaplan, Extranodal (E) lesions in Hodgkin’s disease (HD): Prognosis and response to therapy. Proc Amer Soc Clin Oncol 19: 367, 1978Google Scholar
- 25.doPico GA, AL Wiley Jr, P Rao, and MA Dicksie, Pulmonary reaction to upper mantle radiation therapy for Hodgkin’s disease. Chest 75: 688692, 1979Google Scholar
- 26.Ray, GR, HW Trueblood, and LP Enright, Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiol 96: 175–180, 1970Google Scholar
- 29.DeVita, VT, AA Serpick, and PP Carbone, Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 88 1895, 1970Google Scholar
- 30.DeVita, V, GP Cannellos, S Hubbard, et al, Chemotherapy of Hodgkin’s disease (HD) with MOPP: A 10 year progress report. Proc Amer Soc Clin Oncol 17: 269, 1976Google Scholar